



About Us

Division Overview

Message from the Division Directors

Milestones

Eric K. Rowinsky, MD



Publications

1. Hammond-Thelin LA; Thomas MB; Iwasaki M; Abbruzzese JL; Lassere Y; Meyers CA; Hoff P; de Bono J; Norris J; Matsushita H; Mita A; Rowinsky EK. "Phase I and pharmacokinetic study of 3'-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III, in patients with advanced solid malignancies". *Investigational new drugs*. 2012; 30: 316 (#144135)
2. Rodon J; Jacobs CD; Chu Q; Rowinsky EK; Lopez-Anaya A; Takimoto CH; Wakelee HA. "A phase I pharmacokinetic study of bezarotene with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer (NSCLC)". *Cancer chemotherapy & pharmacology*. 2012; 69: 825 (#144123)
3. Wakelee HA; Takimoto CH; Lopez-Anaya A; Chu Q; Middleton G; Dunlop D; Ramlau R; Leigh N; Rowinsky EK; Hao D; Zatloukal P; Jacobs CD; Rodon J. "The effect of bezarotene on atorvastatin pharmacokinetics: results from a phase I trial of bezarotene plus chemotherapy in patients with advanced non-small cell lung cancer". *Cancer chemotherapy & pharmacology*. 2012; 69: 563 (#144122)
4. Baker, J B; Dutta, D; Watson, D; Maddala, T; Munneke, B M; Shak, S; Rowinsky, E K; Xu, L-A; Harbison, C T; Clark, E A; Mauro, D J; Khambata-Ford, S. "Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer". *British journal of cancer*. 2011; 104: 488 (#144130)
5. Ko AH; Youssoufian H; Gurtler J; Dicke K; Kayaleh O; Lenz HJ; Keaton M; Katz T; Ballal S; Rowinsky EK. "A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma". *Investigational new drugs*. 2011; 1597 (#144127)
6. Mita, A C; Papadopoulos, K; de Jonge, M J A; Schwartz, G; Verweij, J; Mita, M M; Ricart, A; Chu, Q S-C; Tolcher, A W; Wood, L; McCarthy, S; Hamilton, M; Iwata, K; Wacker, B; Witt, K; Rowinsky, E K. "Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer". *British journal of cancer*. 2011; 105: 938 (#144125)
7. Mita, Monica; Kelly, Kevin R; Mita, Alain; Ricart, Alejandro D; Romero, Ofelia; Tolcher, Anthony; Hook, Laurel; Okereke, Chukwuemeka; Krivelevich, Ilya; Rossignol, Daniel P; Giles, Francis J; Rowinsky, Eric K; Takimoto, Chris. "Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies". *Clinical cancer research*. 2011; 17: 193 (#144133)
8. Pacey, Simon; Ratain, Mark J; Flaherty, Keith T; Kaye, Stanley B; Cupit, Lisa; Rowinsky, Eric K; Xia, Chenghua; O'Dwyer, Peter J; Judson, I R. "Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial". *Investigational new drugs*. 2011; 29: 481 (#144128)
9. Rowinsky EK; Schwartz JD; Zojwalla N; Youssoufian H; Fox F; Pultar P; Ludwig DL. "Blockade of Insulin-Like Growth Factor Type-1 Receptor With Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers". *Current drug targets*. 2011; 2016 (#144126)
10. Rowinsky, Eric K. "Targeting the target of rapamycin (TOR): looking to mother nature". *Targeted oncology*. 2011; 6: 1 (#144129)
11. Valle, Juan W; Armstrong, Anne; Newman, Chris; Alakhov, Valery; Pietrzynski, Grzegorz; Brewer, Julie; Campbell, Sue; Corrie, Pippa; Rowinsky, Eric K; Ranson, Malcolm. "A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronic, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction". *Investigational new drugs*. 2011; 29: 1029 (#144124)
12. Wierzbicki, Rafal; Jonker, Derek J; Moore, Malcolm J; Berry, Scott R; Loehrer, Patrick J; Youssoufian, Hagop; Rowinsky, Eric K. "A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining". *Investigational new drugs*. 2011; 29: 167 (#144131)
13. Zhang, W; Winder, T; Ning, Y; Pohl, A; Yang, D; Kahn, M; Lurje, G; Labonte, M J; Wilson, P M; Gordon, M A; Hu-Lieskovan, S; Mauro, D J; Langer, C; Rowinsky, E K; Lenz, H-J. "A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy". *Annals of oncology*. 2011; 22: 104

(#144132)

14. Bonner, James A; Harari, Paul M; Giralt, Jordi; Cohen, Roger B; Jones, Christopher U; Sur, Ranjan K; Raben, David; Baselga, Jose; Spencer, Sharon A; Zhu, Junming; Yousoufian, Hagop; Rowinsky, Eric K; Ang, K Kian. "Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival". *Lancet oncology*. 2010; 11: 21 (#144145)
15. Buckner, Jan C; Forouzesh, Bahram; Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P; Dukart, Gary; Berkenblit, Anna; Rowinsky, Eric K. "Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer". *Investigational new drugs*. 2010; 28: 334 (#144137)
16. Chu, Quincy; Mita, Alain; Forouzesh, Bahram; Tolcher, Anthony W; Schwartz, Gary; Nieto, Antonio; Soto-Matos, Arturo; Alfaro, Vicente; Lebedinsky, Claudia; Rowinsky, Eric K. "Phase I and pharmacokinetic study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors". *Clinical cancer research*. 2010; 16: 2656 (#144138)
17. Guttman-Yassky, Emma; Mita, Alain; De Jonge, Maja; Matthews, Lesley; McCarthy, Sean; Iwata, Kenneth K; Verweij, Jaap; Rowinsky, Eric K; Krueger, James G. "Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib". *European journal of cancer (1990)*. 2010; 46: 2010 (#144136)
18. Kuenen, Bart; Witteveen, Petronella O; Ruijter, Rita; Giaccone, Giuseppe; Dontabhaktuni, Aruna; Fox, Floyd; Katz, Terry; Yousoufian, Hagop; Zhu, Junming; Rowinsky, Eric K; Voest, Emile E. "A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies". *Clinical cancer research*. 2010; 16: 1915 (#144139)
19. Schwartz, Jonathan D; Rowinsky, Eric K; Yousoufian, Hagop; Pytowski, Bronislaw; Wu, Yan. "Vascular endothelial growth factor receptor-1 in human cancer: concise review and rationale for development of IMC-18F1 (Human antibody targeting vascular endothelial growth factor receptor-1)". *Cancer*. 2010; 116: 1027 (#144140)
20. Shah, Gaurav D; Loizos, Nick; Yousoufian, Hagop; Schwartz, Jonathan D; Rowinsky, Eric K. "Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha". *Cancer*. 2010; 116: 1018 (#144142)
21. Sprattlin, Jennifer L; Cohen, Roger B; Eadens, Matthew; Gore, Lia; Camidge, D Ross; Diab, Sami; Leong, Stephen; O'Bryant, Cindy; Chow, Laura Q M; Serkova, Natalie J; Meropol, Neal J; Lewis, Nancy L; Chiorean, E Gabriela; Fox, Floyd; Yousoufian, Hagop; Rowinsky, Eric K; Eckhardt, S Gail. "Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2". *Journal of clinical oncology*. 2010; 28: 780 (#144144)
22. Winder, Thomas; Zhang, Wu; Yang, Dongyun; Ning, Yan; Bohanes, Pierre; Gerger, Armin; Wilson, Peter M; Pohl, Alexandra; Mauro, David J; Langer, Christiane; Rowinsky, Eric K; Lenz, Heinz-Josef. "Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients". *Clinical cancer research*. 2010; 16: 5591 (#144134)
23. Yousoufian, Hagop; Rowinsky, Eric K; Tonra, James; Li, Yiwen. "Targeting FMS-related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC-EB10". *Cancer*. 2010; 116: 1013 (#144141)
24. Zhong, Zhaojing; Carroll, Kyla Driscoll; Policarpio, Desiree; Osborn, Carla; Gregory, Michael; Bassi, Rajiv; Jimenez, Xenia; Prewett, Marie; Liebis, Gregory; Persaud, Kris; Burtrum, Douglas; Wang, Su; Surguladze, David; Ng, Stanley; Griffith, Heather; Balderes, Paul; Doody, Jacqueline; Schwartz, Jonathan D; Yousoufian, Hagop; Rowinsky, Eric K; Ludwig, Dale L; Witte, Larry; Zhu, Zhenping; Wu, Yan. "Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells". *Clinical cancer research*. 2010; 16: 1191 (#144143)
25. Forouzesh, Bahram; Hidalgo, Manuel; Chu, Quincy; Mita, Alain; Mita, Monica; Schwartz, Garry; Jimeno, Jose; Gomez, Javier; Alfaro, Vicente; Lebedinsky, Claudia; Zintl, Patrik; Rowinsky, Eric K. "Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies". *Clinical cancer research*. 2009; 15: 3591 (#144149)
26. Goel, Sanjay; Mita, Alain C; Mita, Monica; Rowinsky, Eric K; Chu, Quincy S; Wong, Nancy; Desjardins, Christopher; Fang, Fang; Jansen, Mendel; Shuster, Dale E; Mani, Sridhar; Takimoto, Chris H. "A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies". *Clinical cancer research*. 2009; 15: 4207 (#144148)
27. Lin, Chia-Chi; Beeram, Muralidhar; Rowinsky, Eric K; Takimoto, Chris H; Ng, Chee M; Geyer, Charles E Jr; Denis, Louis J; De Bono, Johann S; Hao, Desiree; Tolcher, Anthony W; Rha, Sun-Young; Jolivet, Jacques; Patnaik, Amita. "Phase I and pharmacokinetic study of cisplatin and troxacitabine administered intravenously every 28 days in patients with advanced solid malignancies". *Cancer chemotherapy & pharmacology*. 2009; 65: 167 (#144146)
28. Lockhart, A Craig; Calvo, Emiliano; Tolcher, Anthony W; Rowinsky, Eric K; Shackleton, Gareth; Morrison, J Gilmour; Rafi, Rezvan; VerMeulen, Wendy; Rothenberg, Mace L. "A phase I dose-escalation study of SR271425, an intravenously dosed thioxanthone analog, administered weekly in patients with refractory solid tumors". *American journal of clinical oncology*. 2009; 32: 9 (#144150)
29. Mita, Alain C; Denis, Louis J; Rowinsky, Eric K; Debono, Johann S; Goetz, Andrew D; Ochoa, Leonel; Forouzesh, Bahram; Beeram, Muralidhar; Patnaik, Amita; Molpus, Kathleen; Semiond, Dorothee; Besenval,

- Michele; Tolcher, Anthony W. "Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors". *Clinical cancer research*. 2009; 15: 723 (#144151)
30. Mita, Monica; Mita, Alain; Sarantopoulos, John; Takimoto, Chris H; Rowinsky, Eric K; Romero, Ofelia; Angiuli, Patrizia; Allievi, Cecilia; Eisenfeld, Amy; Verschraegen, Claire F. "Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies". *Cancer chemotherapy & pharmacology*. 2009; 64: 287 (#144147)
31. Baker, Laurence H; Rowinsky, Eric K; Mendelson, David; Humerickhouse, Rod A; Knight, Raymond A; Qian, Jiang; Carr, Robert A; Gordon, Gary B; Demetri, George D. "Randomized, phase II study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced soft tissue sarcoma". *Journal of clinical oncology*. 2008; 26: 5583 (#144154)
32. Chu, Quincy S C; Cianfrocca, Mary E; Goldstein, Lori J; Gale, Meg; Murray, Nicholas; Loftiss, Jill; Arya, Nikita; Koch, Kevin M; Pandite, Lini; Fleming, Ronald A; Paul, Elaine; Rowinsky, Eric K. "A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer". *Clinical cancer research*. 2008; 14: 4484 (#144156)
33. de Bono, Johann S; Kristeleit, Rebecca; Tolcher, Anthony; Fong, Peter; Pacey, Simon; Karavasili, Vasilios; Mita, Monica; Shaw, Heather; Workman, Paul; Kaye, Stan; Rowinsky, Eric K; Aherne, Wynne; Atadja, Peter; Scott, Jeffrey W; Patnaik, Amita. "Phase I pharmacokinetic and pharmacodynamic study of LAQ824, a hydroxamate histone deacetylase inhibitor with a heat shock protein-90 inhibitory profile, in patients with advanced solid tumors". *Clinical cancer research*. 2008; 14: 6663 (#144155)
34. Lurje, Georg; Nagashima, Fumio; Zhang, Wu; Yang, Dongyun; Chang, Heung M; Gordon, Michael A; El-Khoueiry, Anthony; Husain, Hatim; Wilson, Peter M; Ladner, Robert D; Mauro, David J; Langer, Christiane; Rowinsky, Eric K; Lenz, Heinz-Josef. "Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab". *Clinical cancer research*. 2008; 14: 7884 (#144153)
35. Mita, Monica M; Mita, Alain C; Chu, Quincy S; Rowinsky, Eric K; Fetterly, Gerald J; Goldston, Michelle; Patnaik, Amita; Mathews, Lesley; Ricart, Alejandro D; Mays, Theresa; Knowles, Heather; Rivera, Victor M; Kreisberg, Jeff; Bedrosian, Camille L; Tolcher, Anthony W. "Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies". *Journal of clinical oncology*. 2008; 26: 361 (#144157)
36. Ricart, Alejandro D; Berlin, Jordan D; Papadopoulos, Kyriakos P; Syed, Samira; Drolet, Daniel W; Quaratino-Baker, Charlotte; Horan, Julie; Chick, Jon; Vermeulen, Wendy; Tolcher, Anthony W; Rowinsky, Eric K; Rothenberg, Mace L. "Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors". *Clinical cancer research*. 2008; 14: 7947 (#144152)
37. Calvo, E; Malik, S N; Siu, L L; Baillargeon, G M; Irish, J; Chin, S F; Santabarbara, P; Kreisberg, J I; Rowinsky, E K; Hidalgo, M. "Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer". *Annals of oncology*. 2007; 18: 761 (#144168)
38. Chu, Quincy S C; Forouzes, Bahram; Syed, Samira; Mita, Monica; Schwartz, Garry; Cooper, Joshua; Curtright, Janet; Rowinsky, Eric K. "A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas". *Investigational new drugs*. 2007; 25: 359 (#144162)
39. Chu, Quincy S C; Schwartz, Garry; de Bono, Johann; Smith, Deborah A; Koch, Kevin M; Versola, Melissa J; Pandite, Lini; Arya, Nikita; Curtright, Jan; Fleming, Ronald A; Ho, Peter T C; Rowinsky, Eric K. "Phase I and pharmacokinetic study of lapatinib in combination with capecitabine in patients with advanced solid malignancies". *Journal of clinical oncology*. 2007; 25: 3753 (#144161)
40. Curran, Desmond; Giralt, Jordi; Harari, Paul M; Ang, K Kian; Cohen, Roger B; Kies, Merrill S; Jassem, Jacek; Baselga, Jose; Rowinsky, Eric K; Amellal, Nadia; Comte, Sylvie; Bonner, James A. "Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab". *Journal of clinical oncology*. 2007; 25: 2191 (#144165)
41. Dragovich, Tomislav; Huberman, Mark; Von Hoff, Daniel D; Rowinsky, Eric K; Nadler, Paul; Wood, Debra; Hamilton, Marta; Hage, George; Wolf, Julie; Patnaik, Amita. "Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial". *Cancer chemotherapy & pharmacology*. 2007; 60: 295 (#144163)
42. Mita, Alain C; Olszanski, Anthony J; Walovitch, Richard C; Perez, Raymond P; MacKay, Kathleen; Tuck, David P; Simmons, Cecilia; Hammond, Susan; Mita, Monica M; Beeram, Muralidhar; Stone, Anne J; Rowinsky, Eric K; Lewis, Lionel D. "Phase I and pharmacokinetic study of AI-850, a novel microparticle hydrophobic drug delivery system for paclitaxel". *Clinical cancer research*. 2007; 13: 3293 (#144164)
43. Mita, Monica M; Rowinsky, Eric K; Forero, Leonardo; Eckhart, S Gail; Izbicka, Elzbieta; Weiss, Geoffrey R; Beeram, Muralidhar; Mita, Alain C; de Bono, Johann S; Tolcher, Anthony W; Hammond, Lisa A; Simmons, Paul; Berg, Kristin; Takimoto, Chris; Patnaik, Amita. "A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma". *Cancer chemotherapy & pharmacology*. 2007; 59: 165 (#144169)
44. Rowinsky, Eric K; Beeram, Muralidhar; Hammond, Lisa A; Schwartz, Garry; De Bono, Johann; Forouzes, Bahram; Chu, Quincy; Latz, Jane E; Hong, Shengyan; John, William; Nguyen, Binh. "A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies". *Clinical cancer research*. 2007; 13: 532 (#144170)

45. Rowinsky, Eric K; Yousseoufian, Hagop; Tonra, James R; Solomon, Phillip; Burtrum, Douglas; Ludwig, Dale L. "IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor". *Clinical cancer research*. 2007; 13: 5549s (#144159)
46. Sparreboom, Alex; Wolff, Antonio C; Mathijssen, Ron H J; Chatelut, Etienne; Rowinsky, Eric K; Verweij, Jaap; Baker, Sharyn D. "Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese". *Journal of clinical oncology*. 2007; 25: 4707 (#144158)
47. Takimoto, Chris H; Hammond-Thelin, Lisa A; Latz, Jane E; Forero, Leonardo; Beeram, Muralidhar; Forouzesh, Bahram; de Bono, Johann; Tolcher, Anthony W; Patnaik, Amita; Monroe, Pamela; Wood, Leslie; Schneck, Karen B; Clark, Romnee; Rowinsky, Eric K. "Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer". *Clinical cancer research*. 2007; 13: 2675 (#144166)
48. Yousseoufian, Hagop; Hicklin, Daniel J; Rowinsky, Eric K. "Review: monoclonal antibodies to the vascular endothelial growth factor receptor-2 in cancer therapy". *Clinical cancer research*. 2007; 13: 5544s (#144160)
49. Yousseoufian, Hagop; Rowinsky, Eric K. "A remedy for biomarker addiction: back to rational anticancer drug development". *Nature clinical practice. Oncology*. 2007; 4: 264 (#144167)
50. Bonner, James A; Harari, Paul M; Giralt, Jordi; Azarnia, Nozar; Shin, Dong M; Cohen, Roger B; Jones, Christopher U; Sur, Ranjan; Raben, David; Jassem, Jacek; Ove, Roger; Kies, Merrill S; Baselga, Jose; Yousseoufian, Hagop; Amellal, Nadia; Rowinsky, Eric K; Ang, K Kian. "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck". *New England journal of medicine*. 2006; 354: 567 (#144180)
51. Erlichman, Charles; Hidalgo, Manuel; Boni, Joseph P; Martins, Patricia; Quinn, Susan E; Zacharchuk, Charles; Amorusi, Peter; Adjei, Alex A; Rowinsky, Eric K. "Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors". *Journal of clinical oncology*. 2006; 24: 2252 (#144177)
52. Hidalgo, Manuel; Buckner, Jan C; Erlichman, Charles; Pollack, Marilyn S; Boni, Joseph P; Dukart, Gary; Marshall, Bonnie; Speicher, Lisa; Moore, Laurence; Rowinsky, Eric K. "A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer". *Clinical cancer research*. 2006; 12: 5755 (#144173)
53. Lee, Carlton K K; Rowinsky, Eric K; Li, Jing; Giles, Francis; Moore, Malcolm J; Hidalgo, Manuel; Capparelli, Edmund; Jolivet, Jacques; Baker, Sharyn D. "Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue". *Clinical cancer research*. 2006; 12: 2158 (#144179)
54. Lenz, Heinz-Josef; Van Cutsem, Eric; Khambata-Ford, Shirin; Mayer, Robert J; Gold, Philip; Stella, Philip; Mirtsching, Barry; Cohn, Allen L; Pippas, Andrew W; Azarnia, Nozar; Tsuchihashi, Zenta; Mauro, David J; Rowinsky, Eric K. "Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines". *Journal of clinical oncology*. 2006; 24: 4914 (#144172)
55. Mita, Alain C; Hammond, Lisa A; Bonate, Peter L; Weiss, Geoffrey; McCreery, Heather; Syed, Samira; Garrison, Mitchell; Chu, Quincy S C; DeBono, Johann S; Jones, Christopher B; Weitman, Steve; Rowinsky, Eric K. "Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors". *Clinical cancer research*. 2006; 12: 5207 (#144174)
56. Mita, Alain C; Sweeney, Christopher J; Baker, Sharyn D; Goetz, Andrew; Hammond, Lisa A; Patnaik, Amita; Tolcher, Anthony W; Villalona-Calero, Miguel; Sandler, Alan; Chaudhuri, Tuhin; Molpus, Kathleen; Latz, Jane E; Simms, Lorinda; Chaudhary, Ajai K; Johnson, Robert D; Rowinsky, Eric K; Takimoto, Chris H. "Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function". *Journal of clinical oncology*. 2006; 24: 552 (#144182)
57. Mita, M M; Ochoa, L; Rowinsky, E K; Kuhn, J; Schwartz, G; Hammond, L A; Patnaik, A; Yeh, I-T; Izbicka, E; Berg, K; Tolcher, A W. "A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer". *Annals of oncology*. 2006; 17: 313 (#144181)
58. Patnaik, Amita; Wood, Debra; Tolcher, Anthony W; Hamilton, Marta; Kreisberg, Jeffrey I; Hammond, Lisa A; Schwartz, Garry; Beeram, Muralidhar; Hidalgo, Manuel; Mita, Monica M; Wolf, Julie; Nadler, Paul; Rowinsky, Eric K. "Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors". *Clinical cancer research*. 2006; 12: 7406 (#144171)
59. Rowinsky, Eric K. "Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors". *Journal of clinical oncology*. 2006; 24: 2981 (#144176)
60. Rowinsky, Eric K; Calvo, Emiliano. "Novel agents that target tublin and related elements". *Seminars in oncology*. 2006; 33: 421 (#144175)
61. Sweeney, Christopher J; Takimoto, Chris H; Latz, Jane E; Baker, Sharyn D; Murry, Daryl J; Krull, James H; Fife, Karen; Battiato, Linda; Cleverly, Ann; Chaudhary, Ajai K; Chaudhuri, Tuhin; Sandler, Alan; Mita, Alain C; Rowinsky, Eric K. "Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer". *Clinical cancer research*. 2006; 12: 536 (#144183)
62. Tolcher, Anthony W; Hao, Desiree; de Bono, Johann; Miller, Alex; Patnaik, Amita; Hammond, Lisa A; Smetzer, Leslie; Van Wart Hood, Jill; Merritt, James; Rowinsky, Eric K; Takimoto, Chris; Von Hoff, Dan;

- Eckhardt, S Gail. "Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer". *Journal of clinical oncology*. 2006; 24: 2052 (#144178)
63. Abou-Alfa, Ghassan K; Rowinsky, Eric K; Patt, Yehuda Z; Schwartz, Gary K; Kelsen, David P; Sharma, Sunil; Siegel, Eve; Becerra, Carlos R; Eckhardt, S Gail; Feit, Kevie; De Jager, Robert; O'Reilly, Eileen M. "A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers". *American journal of clinical oncology*. 2005; 28: 334 (#144189)
 64. Beeram, Muralidhar; Patnaik, Amita; Rowinsky, Eric K. "Raf: a strategic target for therapeutic development against cancer". *Journal of clinical oncology*. 2005; 23: 6771 (#144188)
 65. Calvo, Emiliano; Rowinsky, Eric K. "Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor". *Current oncology reports*. 2005; 7: 123 (#144190)
 66. Calvo, Emiliano; Rowinsky, Eric K. "Clinical experience with monoclonal antibodies to epidermal growth factor receptor". *Current oncology reports*. 2005; 7: 96 (#144191)
 67. Posey, James A 3rd; Saif, M Wasif; Carlisle, Ronda; Goetz, Andrew; Rizzo, Jinee; Stevenson, Suzanne; Rudoltz, Marc S; Kwiatek, Joseph; Simmons, Paul; Rowinsky, Eric K; Takimoto, Chris H; Tolcher, Anthony W. "Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas". *Clinical cancer research*. 2005; 11: 7866 (#144186)
 68. Ricart, Alejandro D; Hammond, Lisa A; Kuhn, John G; Takimoto, Chris H; Goetz, Andrew; Forouzesh, Bahram; Forero, Leonardo; Ochoa-Bayona, Jose L; Berg, Kristin; Tolcher, Anthony W; Rowinsky, Eric K. "Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors". *Clinical cancer research*. 2005; 11: 8728 (#144185)
 69. Rowinsky, Eric K. "Erosion of the principal investigator role in a climate of industry dominance". *European journal of cancer (1990)*. 2005; 41: 2206 (#144187)
 70. Rowinsky, Eric K. "Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents". *Journal of clinical oncology*. 2005; 23: 9394 (#144184)
 71. Calvo, Emiliano; Rowinsky, Eric K. "Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs". *Clinical lung cancer*. 2004; 6 Suppl 1: S35 (#144193)
 72. Calvo, Emiliano; Tolcher, Anthony W; Hammond, Lisa A; Patnaik, Amita; de Bono, Johan S; Eiseman, Irene A; Olson, Stephen C; Lenehan, Peter F; McCreery, Heather; Lorusso, Patricia; Rowinsky, Eric K. "Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study". *Clinical cancer research*. 2004; 10: 7112 (#144195)
 73. Chu, Quincy Siu-Chung; Hammond, Lisa A; Schwartz, Garry; Ochoa, Leonel; Rha, Sun-Young; Denis, Louis; Molpus, Kathleen; Roedig, Brian; Letrent, Stephen P; Damle, Bharat; DeCillis, Arthur P; Rowinsky, Eric K. "Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies". *Clinical cancer research*. 2004; 10: 4913 (#144200)
 74. de Bono, J S; Rha, S Y; Stephenson, J; Schultes, B C; Monroe, P; Eckhardt, G S; Hammond, L A; Whiteside, T L; Nicodemus, C F; Cermak, J M; Rowinsky, E K; Tolcher, A W. "Phase I trial of a murine antibody to MUC1 in patients with metastatic cancer: evidence for the activation of humoral and cellular antitumor immunity". *Annals of oncology*. 2004; 15: 1825 (#144192)
 75. de Bono, Johann S; Tolcher, Anthony W; Forero, Andre; Vanhove, Gertrude F A; Takimoto, Chris; Bauer, Robert J; Hammond, Lisa A; Patnaik, Amita; White, Mark L; Shen, Sui; Khazaeli, Muhammad B; Rowinsky, Eric K; LoBuglio, Albert F. "ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas". *Clinical cancer research*. 2004; 10: 7555 (#144194)
 76. Foon, Kenneth A; Yang, Xiao-Dong; Weiner, Louis M; Belldegrun, Arie S; Figlin, Robert A; Crawford, Jeffrey; Rowinsky, Eric K; Dutcher, Janice P; Vogelzang, Nicholas J; Gollub, Jared; Thompson, John A; Schwartz, Garry; Bukowski, Ronald M; Roskos, Lorin K; Schwab, Gisela M. "Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody". *International journal of radiation oncology biology physics*. 2004; 58: 984 (#144208)
 77. Hammond, Lisa A; Eckardt, John R; Kuhn, John G; Gerson, Stanton L; Johnson, Tom; Smith, Lon; Drengler, Ronald L; Campbell, Elizabeth; Weiss, Geoffrey R; Von Hoff, Daniel D; Rowinsky, Eric K. "A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms". *Clinical cancer research*. 2004; 10: 1645 (#144207)
 78. Lynch, Thomas J; Adjei, Alex A; Bunn, Paul A Jr; DuBois, Raymond N; Gandara, David R; Giaccone, Giuseppe; Govindan, Ramaswamy; Herbst, Roy S; Johnson, Bruce E; Khuri, Fadlo R; Perez-Soler, Roman; Rosell, Rafael; Rowinsky, Eric K; Sandler, Alan B; Scagliotti, Giorgio V; Schiller, Joan H; Shapiro, Geoffrey I; Socinski, Mark A; Hart, Carol S. "Novel agents in the treatment of lung cancer: conference summary statement". *Clinical cancer research*. 2004; 10: 4199s (#144204)
 79. Melendez, Robert F; Harrison, Joseph M; Rowinsky, Eric K; Hammond, Lisa A; Fitzsimmons, Thomas D. "Acute retinal toxicity from the novel anti-tumor agent, Irofulven". *Documenta ophthalmologica*. 2004; 108: 249 (#144205)
 80. Mita, Alain C; Mita, Monica M; Rowinsky, Eric K. "Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer". *Clinical colorectal cancer*. 2004; 4: 107 (#144202)
 81. Perez-Soler, Roman; Chachoua, Abraham; Hammond, Lisa A; Rowinsky, Eric K; Huberman, Mark; Karp, Daniel; Rigas, James; Clark, Gary M; Santabarbara, Pedro; Bonomi, Philip. "Determinants of tumor

- response and survival with erlotinib in patients with non--small-cell lung cancer". *Journal of clinical oncology*. 2004; 22: 3238 (#44862)
82. Rowinsky, Eric K. "A widening prospect: Imatinib and novel applications of targeted therapy". *Seminars in oncology*. 2004; 31: 1 (#144206)
83. Rowinsky, Eric K. "Curtailling the high rate of late-stage attrition of investigational therapeutics against unprecedented targets in patients with lung and other malignancies". *Clinical cancer research*. 2004; 10: 4220s (#144203)
84. Rowinsky, Eric K. "Targeting the molecular target of rapamycin (mTOR)". *Current opinion in oncology*. 2004; 16: 564 (#144196)
85. Rowinsky, Eric K. "The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors". *Annual review of medicine*. 2004; 55: 433 (#144209)
86. Rowinsky, Eric K; Schwartz, Garry H; Gollob, Jared A; Thompson, John A; Vogelzang, Nicholas J; Figlin, Robert; Bukowski, Ronald; Haas, Naomi; Lockbaum, Pamela; Li, Yu-Ping; Arends, Rosalin; Foon, Kenneth A; Schwab, Gisela; Dutcher, Janice. "Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer". *Journal of clinical oncology*. 2004; 22: 3003 (#144201)
87. Royce, Melanie E; Rowinsky, Eric K; Hoff, Paulo M; Coyle, John; DeJager, Robert; Pazdur, Richard; Saltz, Leonard B. "A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for five days every three weeks to patients with metastatic adenocarcinoma of the colon or rectum". *Investigational new drugs*. 2004; 22: 53 (#144210)
88. Schwartz, Garry H; Jones, Christopher B; Garrison, Mitchell; Patnaik, Amita; Takimoto, Chris; McCreery, Heather; Skinner, Michael; Tolcher, Anthony W; Rowinsky, Eric K. "A phase I and pharmacokinetic study of the nonpolyglutamatable thymidylate synthase inhibitor ZD9331 plus docetaxel in patients with advanced solid malignancies". *Investigational new drugs*. 2004; 22: 437 (#144197)
89. Syed, Samira; Takimoto, Chris; Hidalgo, Manuel; Rizzo, Jinee; Kuhn, John G; Hammond, Lisa A; Schwartz, Garry; Tolcher, Anthony; Patnaik, Amita; Eckhardt, S Gail; Rowinsky, Eric K. "A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties". *Clinical cancer research*. 2004; 10: 6512 (#144198)
90. Tolcher, Anthony W; Kuhn, John; Schwartz, Garry; Patnaik, Amita; Hammond, Lisa A; Thompson, Ian; Fingert, Howard; Bushnell, David; Malik, Shazli; Kreisberg, Jeffrey; Izbicka, Elzbieta; Smetzer, Leslie; Rowinsky, Eric K. "A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer". *Clinical cancer research*. 2004; 10: 5048 (#144199)
91. Adjei, Alex A; Rowinsky, Eric K. "Novel anticancer agents in clinical development". *Cancer biology & therapy*. 2003; 2: S5 (#144218)
92. Beeram, Muralidhar; Patnaik, Amita; Rowinsky, Erick K. "Regulation of c-Raf-1: therapeutic implications". *Clinical advances in hematology & oncology : H&O*. 2003; 1: 476 (#144214)
93. Budman, Daniel; Calvert, A. Hilary; Rowinsky, Eric K. "Handbook of anticancer drug development". 2003; (#2111)
94. Cannistra, Stephen A; Bast, Robert C Jr; Berek, Jonathan S; Bookman, Michael A; Crum, Christopher P; DePriest, Paul D; Garber, Judy E; Koh, Wui-Jin; Markman, Maurie; McGuire, William P 3rd; Rose, Peter G; Rowinsky, Eric K; Rustin, Gordon J S; Skates, Steven J; Vasey, Paul A; King, Laura. "Progress in the management of gynecologic cancer: consensus summary statement". *Journal of clinical oncology*. 2003; 21: 129s (#144224)
95. de Bono, Johann S; Tolcher, Anthony W; Rowinsky, Eric K. "Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma". *Seminars in oncology*. 2003; 30: 79 (#144213)
96. de Bono, Johann S; Tolcher, Anthony W; Rowinsky, Eric K. "The future of cytotoxic therapy: selective cytotoxicity based on biology is the key". *Breast cancer research*. 2003; 5: 154 (#144231)
97. Dees, E Claire; Rowinsky, Eric K; Noe, Dennis A; O'Reilly, Seamus; Adjei, Alex A; Elza-Brown, Kathy; Donehower, Ross C. "A phase I and pharmacologic study of pyrazoloacridine and cisplatin in patients with advanced cancer". *Investigational new drugs*. 2003; 21: 75 (#144229)
98. Forouzes, Bahram; Takimoto, Chris H; Goetz, Andrew; Diab, Sami; Hammond, Lisa A; Smetzer, Leslie; Schwartz, Garry; Gazak, Robert; Callaghan, John T; Von Hoff, Daniel D; Rowinsky, Eric K. "A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies". *Clinical cancer research*. 2003; 9: 5540 (#144211)
99. Garrison, Mitchell A; Hammond, Lisa A; Geyer, Charles E Jr; Schwartz, Garry; Tolcher, Anthony W; Smetzer, Leslie; Figueroa, Jose A; Ducharme, Murray; Coyle, John; Takimoto, Chris H; De Jager, Robert L; Rowinsky, Eric K. "A Phase I and pharmacokinetic study of exatecan mesylate administered as a protracted 21-day infusion in patients with advanced solid malignancies". *Clinical cancer research*. 2003; 9: 2527 (#144219)
100. Hao, Desiree; Hammond, Lisa A; Eckhardt, S Gail; Patnaik, Amita; Takimoto, Chris H; Schwartz, Garry H; Goetz, Andrew D; Tolcher, Anthony W; McCreery, Heather A; Mamun, Khalid; Williams, Jon I; Holroyd, Kenneth J; Rowinsky, Eric K. "A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor". *Clinical cancer research*. 2003; 9: 2465 (#144221)
101. Malik, Shazli N; Siu, Lillian L; Rowinsky, Eric K; deGraffenried, Linda; Hammond, Lisa A; Rizzo, Jinee; Bacus, Sarah; Brattain, Michael G; Kreisberg, Jeffrey I; Hidalgo, Manuel. "Pharmacodynamic evaluation of

- the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients". *Clinical cancer research*. 2003; 9: 2478 (#144220)
102. Meropol, Neal J; Somer, Robert A; Gutheil, John; Pelley, Robert J; Modiano, Manuel R; Rowinsky, Eric K; Rothenberg, Mace L; Redding, Spencer W; Serdar, Cuneyt M; Yao, Bin; Heard, Robert; Rosen, Lee S. "Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant". *Journal of clinical oncology*. 2003; 21: 1452 (#144226)
103. Mita, Monica M; Mita, Alain; Rowinsky, Eric K. "Mammalian target of rapamycin: a new molecular target for breast cancer". *Clinical breast cancer*. 2003; 4: 126 (#144222)
104. Mita, Monica M; Mita, Alain; Rowinsky, Eric K. "The molecular target of rapamycin (mTOR) as a therapeutic target against cancer". *Cancer biology & therapy*. 2003; 2: S169 (#144217)
105. O'Reilly, Seamus; O'Hearn, Elizabeth; Struck, Robert F; Rowinsky, Eric K; Molliver, Mark E. "The alkylating agent penclomedine induces degeneration of purkinje cells in the rat cerebellum". *Investigational new drugs*. 2003; 21: 269 (#144215)
106. Patnaik, Amita; Eckhardt, S Gail; Izbicka, Elzbieta; Tolcher, Anthony A; Hammond, Lisa A; Takimoto, Chris H; Schwartz, Garry; McCreery, Heather; Goetz, Andrew; Mori, Masataka; Terada, Kazutoyo; Gentner, Lou; Rybak, Mary-Ellen; Richards, Henry; Zhang, Steven; Rowinsky, Eric K. "A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies". *Clinical cancer research*. 2003; 9: 4761 (#144212)
107. Rowinsky, Eric K. "Challenges of developing therapeutics that target signal transduction in patients with gynecologic and other malignancies". *Journal of clinical oncology*. 2003; 21: 175s (#144223)
108. Rowinsky, Eric K. "Crossing the cancer cell membrane to improve clinical outcomes". *Oncologist*. 2003; 8 Suppl 3: 1 (#144234)
109. Rowinsky, Eric K. "Signal events: Cell signal transduction and its inhibition in cancer". *Oncologist*. 2003; 8 Suppl 3: 5 (#144233)
110. Rowinsky, Eric K; Rizzo, Jinee; Ochoa, Leonel; Takimoto, Chris H; Forouzes, Bahram; Schwartz, Garry; Hammond, Lisa A; Patnaik, Amita; Kwiatek, Joseph; Goetz, Andrew; Denis, Louis; McGuire, Jeffrey; Tolcher, Anthony W. "A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies". *Journal of clinical oncology*. 2003; 21: 148 (#144232)
111. Schwartz, G H; Patnaik, A; Hammond, L A; Rizzo, J; Berg, K; Von Hoff, D D; Rowinsky, E K. "A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignancies". *Annals of oncology*. 2003; 14: 775 (#144225)
112. Sledge, George W; Neuberg, Donna; Bernardo, Patricia; Ingle, James N; Martino, Silvana; Rowinsky, Eric K; Wood, William C. "Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193)". *Journal of clinical oncology*. 2003; 21: 588 (#144228)
113. Takimoto, Chris H; Rowinsky, Eric K. "Dose-intense paclitaxel: deja vu all over again?". *Journal of clinical oncology*. 2003; 21: 2810 (#144216)
114. Tolcher, A W; Gerson, S L; Denis, L; Geyer, C; Hammond, L A; Patnaik, A; Goetz, A D; Schwartz, G; Edwards, T; Reyderman, L; Statkevich, P; Cutler, D L; Rowinsky, E K. "Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules". *British journal of cancer*. 2003; 88: 1004 (#144227)
115. Tolcher, Anthony W; Ochoa, Leonel; Hammond, Lisa A; Patnaik, Amita; Edwards, Tam; Takimoto, Chris; Smith, Lon; de Bono, Johann; Schwartz, Garry; Mays, Theresa; Jonak, Zdenka L; Johnson, Randall; DeWitte, Mark; Martino, Helen; Audette, Charlene; Maes, Kate; Chari, Ravi V J; Lambert, John M; Rowinsky, Eric K. "Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study". *Journal of clinical oncology*. 2003; 21: 211 (#144230)
116. Baker, Sharyn D; Verweij, Jaap; Rowinsky, Eric K; Donehower, Ross C; Schellens, Jan H M; Grochow, Louise B; Sparreboom, Alex. "Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001". *Journal of the National Cancer Institute*. 2002; 94: 1883 (#144235)
117. de Bono, Johann S; Rowinsky, Eric K. "The ErbB receptor family: a therapeutic target for cancer". *Trends in molecular medicine*. 2002; 8: S19 (#144248)
118. de Bono, Johann S; Rowinsky, Eric K. "Therapeutics targeting signal transduction for patients with colorectal carcinoma". *British medical bulletin*. 2002; 64: 227 (#144243)
119. de Bono, Johann S; Stephenson, Joseph Jr; Baker, Sharyn D; Hidalgo, Manuel; Patnaik, Amita; Hammond, Lisa A; Weiss, Geoffrey; Goetz, Andrew; Siu, Lillian; Simmons, Cecelia; Jolivet, Jacques; Rowinsky, Eric K. "Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies". *Journal of clinical oncology*. 2002; 20: 96 (#144246)
120. Hao, Desiree; Rowinsky, Eric K. "Inhibiting signal transduction: recent advances in the development of receptor tyrosine kinase and Ras inhibitors". *Cancer investigation*. 2002; 20: 387 (#144244)
121. Lobell, Robert B; Liu, Dongming; Buser, Carolyn A; Davide, Joseph P; DePuy, Elizabeth; Hamilton, Kelly; Koblan, Kenneth S; Lee, Yih; Mosser, Scott; Motzel, Sherri L; Abbruzzese, James L; Fuchs, Charles S; Rowinsky, Eric K; Rubin, Eric H; Sharma, Sunil; Deutsch, Paul J; Mazina, Kathryn E; Morrison, Briggs W; Wildonger, Lynne; Yao, Siu-Long; Kohl, Nancy E. "Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-1". *Molecular cancer therapeutics*. 2002; 1: 747 (#144240)
122. Mould, Diane R; Holford, Nicholas H G; Schellens, Jan H M; Beijnen, Jos H; Hutson, Paul R; Rosing, Hilde;

- ten Bokkel Huinink, Willem W; Rowinsky, Eric K; Schiller, Joan H; Russo, Mark; Ross, Graham. "Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors". *Clinical pharmacology & therapeutics*. 2002; 71: 334 (#144241)
123. Patnaik, Amita; Rowinsky, Eric K; Villalona, Miguel A; Hammond, Lisa A; Britten, Carolyn D; Siu, Lillian L; Goetz, Andrew; Felton, Sally A; Burton, Susan; Valone, Frank H; Eckhardt, S Gail. "A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies". *Clinical cancer research*. 2002; 8: 2142 (#144239)
124. Ranson, Malcolm; Hammond, Lisa A; Ferry, David; Kris, Mark; Tullo, Andrew; Murray, Philip I; Miller, Vince; Averbuch, Steve; Ochs, Judy; Morris, Charles; Feyereislova, Andrea; Swaisland, Helen; Rowinsky, Eric K. "ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial". *Journal of clinical oncology*. 2002; 20: 2240 (#144242)
125. Rowinsky, Eric K. "Taxane analogues: distinguishing royal robes from the "Emperor's New Clothes"". *Clinical cancer research*. 2002; 8: 2759 (#144237)
126. Rowinsky, Eric K. "Weekly topotecan: an alternative to topotecan's standard daily x 5 schedule?". *Oncologist*. 2002; 7: 324 (#144247)
127. Siu, Lillian L; Rowinsky, Eric K; Hammond, Lisa A; Weiss, Geoffrey R; Hidalgo, Manuel; Clark, Gary M; Moczygemba, Judy; Choi, Les; Linnartz, Ron; Barbet, Nicholas C; Sklenar, Ivo T; Capdeville, Renaud; Gan, Gregory; Porter, Carl W; Von Hoff, Daniel D; Eckhardt, S Gail. "A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies". *Clinical cancer research*. 2002; 8: 2157 (#144238)
128. Tolcher, Anthony W; Takimoto, Chris H; Rowinsky, Eric K. "The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?". *Journal of clinical oncology*. 2002; 20: 4276 (#144236)
129. Villalona-Calero, Miguel A; Eckhardt, S Gail; Weiss, Geoffrey; Hidalgo, Manuel; Beijnen, Jos H; van Kesteren, Charlotte; Rosing, Hilde; Campbell, Elizabeth; Kraynak, Maura; Lopez-Lazaro, Luis; Guzman, Cecilia; Von Hoff, Daniel D; Jimeno, Jose; Rowinsky, Eric K. "A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies". *Clinical cancer research*. 2002; 8: 75 (#144245)
130. Britten, C D; Rowinsky, E K; Soignet, S; Patnaik, A; Yao, S L; Deutsch, P; Lee, Y; Lobell, R B; Mazina, K E; McCreery, H; Pezzuli, S; Spriggs, D. "A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778,123 in patients with solid malignancies". *Clinical cancer research*. 2001; 7: 3894 (#144249)
131. Gore, S D; Weng, L J; Zhai, S; Figg, W D; Donehower, R C; Dover, G J; Grever, M; Griffin, C A; Grochow, L B; Rowinsky, E K; Zabalena, Y; Hawkins, A L; Burks, K; Miller, C B. "Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia". *Clinical cancer research*. 2001; 7: 2330 (#144251)
132. Hidalgo, M; Aylesworth, C; Hammond, L A; Britten, C D; Weiss, G; Stephenson, J Jr; Schwartz, G; Patnaik, A; Smith, L; Molpus, K; Felton, S; Gupta, E; Ferrante, K J; Tortora, A; Sonnichsen, D S; Skillings, J; Rowinsky, E K. "Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel". *Journal of clinical oncology*. 2001; 19: 2493 (#144257)
133. Hidalgo, M; Siu, L L; Nemunaitis, J; Rizzo, J; Hammond, L A; Takimoto, C; Eckhardt, S G; Tolcher, A; Britten, C D; Denis, L; Ferrante, K; Von Hoff, D D; Silberman, S; Rowinsky, E K. "Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies". *Journal of clinical oncology*. 2001; 19: 3267 (#144254)
134. Holmes, F A; Rowinsky, E K. "Pharmacokinetic profiles of doxorubicin in combination with taxanes". *Seminars in oncology*. 2001; 28: 8 (#144252)
135. Lakhanpal, S; Donehower, R C; Rowinsky, E K. "Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma". *Investigational new drugs*. 2001; 19: 69 (#144259)
136. O'Reilly, S; Hartman, N R; Bowling, K M; Rowinsky, E K; Donehower, R C; Collins, J; Strong, J M. "Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedine". *Cancer chemotherapy & pharmacology*. 2001; 48: 223 (#144250)
137. Schwartz, G; Johnson, T R; Goetz, A; Burris, H; Smetzer, L; Lampkin, T; Sailstad, J; Hohneker, J A; Von Hoff, D D; Rowinsky, E K. "A phase I and pharmacokinetic study of 1843U89, a noncompetitive inhibitor of thymidylate synthase, in patients with advanced solid malignancies". *Clinical cancer research*. 2001; 7: 1901 (#144253)
138. Tolcher, A W; Eckhardt, S G; Kuhn, J; Hammond, L; Weiss, G; Rizzo, J; Aylesworth, C; Hidalgo, M; Patnaik, A; Schwartz, G; Felton, S; Campbell, E; Rowinsky, E K. "Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties". *Journal of clinical oncology*. 2001; 19: 2937 (#144255)
139. Villalona-Calero, M A; Blum, J L; Jones, S E; Diab, S; Elledge, R; Khoury, P; Von Hoff, D; Kraynak, M; Moczygemba, J; Kromelis, P; Griffin, T; Rowinsky, E K. "A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients". *Annals of oncology*. 2001; 12: 605 (#144256)
140. Villalona-Calero, M A; Eder, J P; Topmeyer, D L; Allen, L F; Fram, R; Velagapudi, R; Myers, M; Amato, A; Kagen-Hallet, K; Razvillas, B; Kufe, D W; Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacokinetic study of LU79553, a DNA intercalating bisnaphthalimide, in patients with solid malignancies". *Journal of*

- clinical oncology*. 2001; 19: 857 (#144258)
141. Baker, S D; Diasio, R B; O'Reilly, S; Lucas, V S; Khor, S P; Sartorius, S E; Donehower, R C; Grochow, L B; Spector, T; Hohneker, J A; Rowinsky, E K. "Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil". *Journal of clinical oncology*. 2000; 18: 915 (#144271)
142. Bonomi, P; Perez-Soler, R; Chachoua, A; Huberman, M; Karp, D; Rigas, J; Hammond, L; Rowinsky, E; Preston, G; Ferrente, KJ; Allen, LF. "A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), CP-358,774, following platinum-based chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)". *Clinical cancer research*. 2000; 6: 4544S (#54443)
143. Britten, C D; Baker, S D; Denis, L J; Johnson, T; Drengler, R; Siu, L L; Duchin, K; Kuhn, J; Rowinsky, E K. "Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel". *Clinical cancer research*. 2000; 6: 3459 (#144265)
144. Britten, C D; Rowinsky, E K; Baker, S D; Weiss, G R; Smith, L; Stephenson, J; Rothenberg, M; Smetzer, L; Cramer, J; Collins, W; Von Hoff, D D; Eckhardt, S G. "A phase I and pharmacokinetic study of the mitochondrial-specific rhodocyanine dye analog MKT 077". *Clinical cancer research*. 2000; 6: 42 (#144272)
145. Eckhardt, S G; Baker, S D; Britten, C D; Hidalgo, M; Siu, L; Hammond, L A; Villalona-Calero, M A; Felton, S; Drengler, R; Kuhn, J G; Clark, G M; Smith, S L; MacDonald, J R; Smith, C; Moczygemba, J; Weitman, S; Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies". *Journal of clinical oncology*. 2000; 18: 4086 (#144261)
146. Gallo, J M; Laub, P B; Rowinsky, E K; Grochow, L B; Baker, S D. "Population pharmacokinetic model for topotecan derived from phase I clinical trials". *Journal of clinical oncology*. 2000; 18: 2459 (#144267)
147. Hammond, L A; Hilsenbeck, S G; Eckhardt, S G; Marty, J; Mangold, G; MacDonald, J R; Rowinsky, E K; Von Hoff, D D; Weitman, S. "Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with topotecan or paclitaxel in the MV522 lung carcinoma xenograft model". *European journal of cancer (1990)*. 2000; 36: 2430 (#144262)
148. Hidalgo, M; Rowinsky, E K. "The rapamycin-sensitive signal transduction pathway as a target for cancer therapy". *Oncogene*. 2000; 19: 6680 (#144260)
149. Hidalgo, M; Villalona-Calero, M A; Eckhardt, S G; Drengler, R L; Rodriguez, G; Hammond, L A; Diab, S G; Weiss, G; Garner, A M; Campbell, E; Davidson, K; Louie, A; O'Neil, J D; von Borstel, R; Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies". *Journal of clinical oncology*. 2000; 18: 167 (#144275)
150. John, W; Picus, J; Blanke, C D; Clark, J W; Schulman, L N; Rowinsky, E K; Thornton, D E; Loehrer, P J. "Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study". *Cancer*. 2000; 88: 1807 (#144268)
151. Ochoa, L; Hurwitz, H I; Wilding, G; Cohen, D; Thomas, J P; Schwartz, G; Monroe, P; Petros, W P; Ertel, V P; Hsieh, A; Hoffman, C; Drengler, R; Magnum, S; Rowinsky, E K. "Pharmacokinetics and bioequivalence of a combined oral formulation of eniluracil, an inactivator of dihydropyrimidine dehydrogenase, and 5-fluorouracil in patients with advanced solid malignancies". *Annals of oncology*. 2000; 11: 1313 (#144264)
152. Patnaik, A; Rowinsky, E K; Tammara, B K; Hidalgo, M; Drengler, R L; Garner, A M; Siu, L L; Hammond, L A; Felton, S A; Mallikaarjun, S; Von Hoff, D D; Eckhardt, S G. "Phase I and pharmacokinetic study of the differentiating agent vesnarinone in combination with gemcitabine in patients with advanced cancer". *Journal of clinical oncology*. 2000; 18: 3974 (#144263)
153. Rowinsky, E K. "The pursuit of optimal outcomes in cancer therapy in a new age of rationally designed target-based anticancer agents". *Drugs*. 2000; 60 Suppl 1: 1 (#144273)
154. Rowinsky, E K; Humphrey, R; Hammond, L A; Aylesworth, C; Smetzer, L; Hidalgo, M; Morrow, M; Smith, L; Garner, A; Sorensen, J M; Von Hoff, D D; Eckhardt, S G. "Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies". *Journal of clinical oncology*. 2000; 18: 178 (#144274)
155. Rowinsky, E K; Johnson, T R; Geyer, C E Jr; Hammond, L A; Eckhardt, S G; Drengler, R; Smetzer, L; Coyle, J; Rizzo, J; Schwartz, G; Tolcher, A; Von Hoff, D D; De Jager, R L. "DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies". *Journal of clinical oncology*. 2000; 18: 3151 (#144266)
156. Tolcher, A W; Aylesworth, C; Rizzo, J; Izbicka, E; Campbell, E; Kuhn, J; Weiss, G; Von Hoff, D D; Rowinsky, E K. "A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors". *Annals of oncology*. 2000; 11: 333 (#144270)
157. Zucker, S; Eckhardt, S G; Rowinsky, E K. "Plasma MMPs as surrogates of BAY 12-9566". *Journal of clinical oncology*. 2000; 18: 1805 (#144269)
158. Baker, S D; Wirth, M; Statkevich, P; Reidenberg, P; Alton, K; Sartorius, S E; Dugan, M; Cutler, D; Batra, V; Grochow, L B; Donehower, R C; Rowinsky, E K. "Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer". *Clinical cancer research*. 1999; 5: 309 (#144291)
159. Britten, C D; Hilsenbeck, S G; Eckhardt, S G; Marty, J; Mangold, G; MacDonald, J R; Rowinsky, E K; Von Hoff, D D; Weitman, S. "Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model". *Cancer research*. 1999; 59: 1049 (#144288)
160. Britten, C D; Izbicka, E; Hilsenbeck, S; Lawrence, R; Davidson, K; Cerna, C; Gomez, L; Rowinsky, E K;

- Weitman, S; Von Hoff, D D. "Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay". *Cancer chemotherapy & pharmacology*. 1999; 44: 105 (#144293)
161. Britten, C D; Rowinsky, E K; Baker, S D; Agarwala, S S; Eckardt, J R; Barrington, R; Diab, S G; Hammond, L A; Johnson, T; Villalona-Calero, M; Fraass, U; Statkevich, P; Von Hoff, D D; Eckhardt, S G. "A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies". *Clinical cancer research*. 1999; 5: 1629 (#144283)
162. Diab, S G; Baker, S D; Joshi, A; Burris, H A; Cobb, P W; Villalona-Calero, M A; Eckhardt, S G; Weiss, G R; Rodriguez, G I; Drengler, R; Kraynak, M; Hammond, L; Finizio, M; Von Hoff, D D; Rowinsky, E K. "A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors". *Clinical cancer research*. 1999; 5: 299 (#144292)
163. Eckhardt, S G; Rizzo, J; Sweeney, K R; Cropp, G; Baker, S D; Kraynak, M A; Kuhn, J G; Villalona-Calero, M A; Hammond, L; Weiss, G; Thurman, A; Smith, L; Drengler, R; Eckardt, J R; Moczygemba, J; Hannah, A L; Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors". *Journal of clinical oncology*. 1999; 17: 1095 (#144286)
164. Fracasso, P M; Tan, B R Jr; Grief, M; Stephenson, J Jr; Liapis, H; Umbeck, N L; Von Hoff, D D; Rowinsky, E K. "Membranoproliferative glomerulonephritis following gemcitabine and vinorelbine chemotherapy for peritoneal mesothelioma". *Journal of the National Cancer Institute*. 1999; 91: 1779 (#144278)
165. Hammond, L A; Eckardt, J R; Baker, S D; Eckhardt, S G; Dugan, M; Forral, K; Reidenberg, P; Statkevich, P; Weiss, G R; Rinaldi, D A; Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies". *Journal of clinical oncology*. 1999; 17: 2604 (#144282)
166. Hidalgo, M; Izbicka, E; Cerna, C; Gomez, L; Rowinsky, E K; Weitman, S D; Von Hoff, D D. "Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay". *Anti-cancer drugs*. 1999; 10: 295 (#144287)
167. Hidalgo, M; Izbicka, E; Eckhardt, S G; MacDonald, J R; Cerna, C; Gomez, L; Rowinsky, E K; Weitman, S D; Von Hoff, D D. "Antitumor activity of MGI 114 (6-hydroxymethylacylfulvene, HMAF), a semisynthetic derivative of illudin S, against adult and pediatric human tumor colony-forming units". *Anti-cancer drugs*. 1999; 10: 837 (#144279)
168. Lawrence, R A; Izbicka, E; De Jager, R L; Tohgo, A; Clark, G M; Weitman, S D; Rowinsky, E K; Von Hoff, D D. "Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells". *Anti-cancer drugs*. 1999; 10: 655 (#144281)
169. Petit, T; Aylesworth, C; Burris, H; Ravdin, P; Rodriguez, G; Smith, L; Peacock, N; Smetzer, L; Bellet, R; Von Hoff, D D; Rowinsky, E K. "A phase I study of docetaxel and 5-fluorouracil in patients with advanced solid malignancies". *Annals of oncology*. 1999; 10: 223 (#144290)
170. Rowinsky, E K. "Novel radiation sensitizers targeting tissue hypoxia". *Oncology*. 1999; 13: 61 (#144280)
171. Rowinsky, E K. "On pushing the outer edge of the outer edge of paclitaxel's dosing envelope". *Clinical cancer research*. 1999; 5: 481 (#144289)
172. Rowinsky, E K; Jiroutek, M; Bonomi, P; Johnson, D; Baker, S D. "Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin". *Clinical cancer research*. 1999; 5: 767 (#144285)
173. Rowinsky, E K; Windle, J J; Von Hoff, D D. "Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development". *Journal of clinical oncology*. 1999; 17: 3631 (#144277)
174. Villalona-Calero, M A; Petit, T; Kuhn, J; Cobb, P; Kraynak, M; Eckhardt, S G; Drengler, R; Simmons, C; Santabarbara, P; Von Hoff, D D; Rowinsky, E K. "A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies". *Clinical cancer research*. 1999; 5: 3369 (#144276)
175. Villalona-Calero, M A; Weiss, G R; Burris, H A; Kraynak, M; Rodrigues, G; Drengler, R L; Eckhardt, S G; Reigner, B; Moczygemba, J; Burger, H U; Griffin, T; Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies". *Journal of clinical oncology*. 1999; 17: 1915 (#144284)
176. Adjei, A A; Charron, M; Rowinsky, E K; Svingen, P A; Miller, J; Reid, J M; Sebolt-Leopold, J; Ames, M M; Kaufmann, S H. "Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II". *Clinical cancer research*. 1998; 4: 683 (#144303)
177. Eckhardt, S G; Baker, S D; Eckardt, J R; Burke, T G; Warner, D L; Kuhn, J G; Rodriguez, G; Fields, S; Thurman, A; Smith, L; Rothenberg, M L; White, L; Wissel, P; Kunka, R; DePee, S; Littlefield, D; Burris, H A; Von Hoff, D D; Rowinsky, E K. "Phase I and pharmacokinetic study of GI147211, a water-soluble camptothecin analogue, administered for five consecutive days every three weeks". *Clinical cancer research*. 1998; 4: 595 (#144304)
178. Gore, S D; Rowinsky, E K; Miller, C B; Griffin, C; Chen, T L; Borowitz, M; Donehower, R C; Burks, K L; Armstrong, D K; Burke, P J; Grever, M R; Kaufmann, S H. "A phase II 'window' study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia". *Clinical cancer research*. 1998; 4: 2677 (#144295)
179. Hammond, L A; Eckardt, J R; Ganapathi, R; Burris, H A; Rodriguez, G A; Eckhardt, S G; Rothenberg, M L; Weiss, G R; Kuhn, J G; Hodges, S; Von Hoff, D D; Rowinsky, E K. "A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide". *Clinical cancer research*. 1998; 4: 1459 (#144299)
180. Hidalgo, M; Rodriguez, G; Kuhn, J G; Brown, T; Weiss, G; MacGovren, J P; Von Hoff, D D; Rowinsky, E K.

- "A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies". *Clinical cancer research*. 1998; 4: 2763 (#144294)
181. Kennedy, M J; Zahurak, M L; Donehower, R C; Noe, D; Grochow, L B; Sartorius, S; Chen, T L; Bowling, K; Duerr, M; Rowinsky, E K. "Sequence-dependent hematological toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet". *Clinical cancer research*. 1998; 4: 349 (#144306)
182. O'Reilly, S; Baker, S D; Sartorius, S; Rowinsky, E K; Finizio, M; Lubiniecki, G M; Grochow, L B; Gray, J E; Pieniaszek, H J Jr; Donehower, R C. "A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion". *Annals of oncology*. 1998; 9: 101 (#144307)
183. Rodriguez, G I; Kuhn, J G; Weiss, G R; Hilsenbeck, S G; Eckardt, J R; Thurman, A; Rinaldi, D A; Hodges, S; Von Hoff, D D; Rowinsky, E K. "A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea". *Blood*. 1998; 91: 1533 (#144302)
184. Rothenberg, M L; Kuhn, J G; Schaaf, L J; Drengler, R L; Eckhardt, S G; Villalona-Calero, M A; Hammond, L; Miller, L L; Petit, R G; Rowinsky, E K; Von Hoff, D D. "Alternative dosing schedules for irinotecan". *Oncology*. 1998; 12: 68 (#144298)
185. Rowinsky EK. "Novel Natural Products and Other Anticancer Therapeutics: 1998". *Cancer control*. 1998; 5: 12 (#144301)
186. Rowinsky, E K; Baker, S D; Burks, K; O'Reilly, S; Donehower, R C; Grochow, L B. "High-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer: a phase II and pharmacodynamic study". *Annals of oncology*. 1998; 9: 173 (#144305)
187. Rowinsky, E K; Smith, L; Wang, Y M; Chaturvedi, P; Villalona, M; Campbell, E; Aylesworth, C; Eckhardt, S G; Hammond, L; Kravak, M; Drengler, R; Stephenson, J Jr; Harding, M W; Von Hoff, D D. "Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP". *Journal of clinical oncology*. 1998; 16: 2964 (#144296)
188. Siu, L L; Attardo, G; Izbicka, E; Lawrence, R; Cerna, C; Gomez, L; Davidson, K; Finkle, C; Marsolais, C; Rowinsky, E K; Von Hoff, D D. "Activity of (-)-2'-deoxy-3'-oxacytidine (BCH-4556) against human tumor colony-forming units". *Annals of oncology*. 1998; 9: 885 (#144297)
189. Siu, L L; Rowinsky, E K. "A risk-benefit assessment of irinotecan in solid tumours". *Drug safety*. 1998; 18: 395 (#144300)
190. Siu, L L; Von Hoff, D D; Rephaeli, A; Izbicka, E; Cerna, C; Gomez, L; Rowinsky, E K; Eckhardt, S G. "Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units". *Investigational new drugs*. 1998; 16: 113 (#144308)
191. Adjei, A A; Budihardjo, I I; Rowinsky, E K; Kottke, T J; Svingen, P A; Buckwalter, C A; Grochow, L B; Donehower, R C; Kaufmann, S H. "Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: inhibition of platinum-DNA adduct removal". *Clinical cancer research*. 1997; 3: 761 (#144317)
192. Hortobagyi GN; Sledge GW Jr; Rowinsky EK. "What New Drugs, Biologics, and Treatment Approaches Show Promise in Breast Cancer?". *Cancer control*. 1997; 4: 34 (#144315)
193. Kaufmann, S H; Svingen, P A; Gore, S D; Armstrong, D K; Cheng, Y C; Rowinsky, E K. "Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells". *Blood*. 1997; 89: 2098 (#144320)
194. O'Reilly, S; Fleming, G F; Barker, S D; Walczak, J R; Bookman, M A; McGuire, W P 3rd; Schilder, R J; Alvarez, R D; Armstrong, D K; Horowitz, I R; Ozols, R F; Rowinsky, E K. "Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study". *Journal of clinical oncology*. 1997; 15: 177 (#144326)
195. O'Reilly, S; Grochow, L B; Donehower, R C; Chen, T L; Bowling, K; Hartman, N R; Struck, R F; Rowinsky, E K. "Phase I and pharmacologic study of penclomedine, a novel alkylating agent, in patients with solid tumors". *Journal of clinical oncology*. 1997; 15: 1974 (#144318)
196. O'Reilly, S; Rowinsky, E K. "Experimental chemotherapeutic agents for the treatment of colorectal carcinoma". *Hematology-oncology clinics of North America*. 1997; 11: 721 (#144313)
197. Raymond, E; Burris, H A; Rowinsky, E K; Eckardt, J R; Rodriguez, G; Smith, L; Weiss, G; Von Hoff, D D. "Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated non-small-cell lung carcinoma". *Annals of oncology*. 1997; 8: 1003 (#144312)
198. Raymond, E; Hanauske, A; Faivre, S; Izbicka, E; Clark, G; Rowinsky, E K; Von Hoff, D D. "Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units". *Anti-cancer drugs*. 1997; 8: 379 (#144319)
199. Rowinsky, E K. "Paclitaxel pharmacology and other tumor types". *Seminars in oncology*. 1997; 24: S19 (#144309)
200. Rowinsky, E K. "The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents". *Annual review of medicine*. 1997; 48: 353 (#144324)
201. Rowinsky, E K. "The taxanes: dosing and scheduling considerations". *Oncology*. 1997; 11: 7 (#144323)
202. Rowinsky, E K; Flood, W A; Sartorius, S E; Bowling, K M; Ettinger, D S. "Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer". *Investigational new drugs*. 1997; 15: 129 (#144325)
203. Rowinsky, E K; Kaufmann, S H. "Topotecan in combination chemotherapy". *Seminars in oncology*. 1997; 24: S20 (#144310)
204. Rowinsky, E K; Long, G S; Noe, D A; Grochow, L B; Bowling, M K; Sartorius, S E; Donehower, R C. "Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent". *Clinical cancer research*.

- 1997; 3: 401 (#144322)
205. Rowinsky, E K; Verweij, J. "Review of phase I clinical studies with topotecan". *Seminars in oncology*. 1997; 24: S20 (#144311)
206. Sledge GW Jr; Rowinsky EK; Hortobagyi GN; Vaughan W; Horton J. "What are the Roles of the Taxanes in Breast Cancer". *Cancer control*. 1997; 4: 23 (#144316)
207. Su, H; Chen, T L; Hausheer, F H; Rowinsky, E K. "Novel high-performance liquid chromatographic assay using fluorescence detection for the quantitation of plasma gamma-methylene-10-deazaaminopterin and its major metabolite, 7-hydroxy-gamma-methylene-10-deazaaminopterin, in patients with solid cancers in a phase I trial". *Journal of chromatography. B. Biomedical sciences & applications*. 1997; 695: 401 (#144314)
208. Baker, S D; Khor, S P; Adjei, A A; Doucette, M; Spector, T; Donehower, R C; Grochow, L B; Sartorius, S E; Noe, D A; Hohneker, J A; Rowinsky, E K. "Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase". *Journal of clinical oncology*. 1996; 14: 3085 (#144329)
209. Hartman, N R; O'Reilly, S; Rowinsky, E K; Collins, J M; Strong, J M. "Murine and human in vivo penclomedine metabolism". *Clinical cancer research*. 1996; 2: 953 (#144335)
210. Kaufmann, S H; Gore, S D; Letendre, L; Svingen, P A; Kottke, T; Buckwalter, C A; Jones, R J; Grochow, L B; Burke, P J; Donehower, R C; Rowinsky, E K. "Factors affecting topotecan sensitivity in human leukemia samples". *Annals of the New York Academy of Sciences*. 1996; 803: 128 (#144327)
211. Kaufmann, S H; Peereboom, D; Buckwalter, C A; Svingen, P A; Grochow, L B; Donehower, R C; Rowinsky, E K. "Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines". *Journal of the National Cancer Institute*. 1996; 88: 734 (#144333)
212. Kennedy, M J; Zahurak, M L; Donehower, R C; Noe, D A; Sartorius, S; Chen, T L; Bowling, K; Rowinsky, E K. "Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer". *Journal of clinical oncology*. 1996; 14: 783 (#144338)
213. O'Reilly, S; Donehower, R C; Rowinsky, E K; Ord, S; Grochow, L B. "A phase II trial of topotecan in patients with previously untreated pancreatic cancer". *Anti-cancer drugs*. 1996; 7: 410 (#144334)
214. O'Reilly, S; Hartman, N R; Grossman, S A; Strong, J M; Struck, R F; Eller, S; Lesser, G J; Donehower, R C; Rowinsky, E K. "Tissue and tumor distribution of C-penclomedine in rats". *Clinical cancer research*. 1996; 2: 541 (#144337)
215. O'Reilly, S; Rowinsky, E K. "The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996". *Critical reviews in oncology-hematology*. 1996; 24: 47 (#144332)
216. O'Reilly, S; Rowinsky, E K; Slichenmyer, W; Donehower, R C; Forastiere, A A; Ettinger, D S; Chen, T L; Sartorius, S; Grochow, L B. "Phase I and pharmacologic study of topotecan in patients with impaired renal function". *Journal of clinical oncology*. 1996; 14: 3062 (#144331)
217. Rowinsky, E K; Grochow, L B; Sartorius, S E; Bowling, M K; Kaufmann, S H; Peereboom, D; Donehower, R C. "Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors". *Journal of clinical oncology*. 1996; 14: 1224 (#144336)
218. Rowinsky, E K; Kaufmann, S H; Baker, S D; Grochow, L B; Chen, T L; Peereboom, D; Bowling, M K; Sartorius, S E; Ettinger, D S; Forastiere, A A; Donehower, R C. "Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence". *Journal of clinical oncology*. 1996; 14: 3074 (#144330)
219. Rowinsky, E K; Kaufmann, S H; Baker, S D; Miller, C B; Sartorius, S E; Bowling, M K; Chen, T L; Donehower, R C; Gore, S D. "A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia". *Clinical cancer research*. 1996; 2: 1921 (#144328)
220. Rowinsky, E K; Lucas, V S; Hsieh, A L; Wargin, W A; Hohneker, J A; Lubejko, B; Sartorius, S E; Donehower, R C. "The effects of food and divided dosing on the bioavailability of oral vinorelbine". *Cancer chemotherapy & pharmacology*. 1996; 39: 9 (#144339)
221. Kennedy, M J; Donehower, R C; Rowinsky, E K. "Treatment of metastatic breast cancer with combination paclitaxel/cyclophosphamide". *Seminars in oncology*. 1995; 22: 23 (#144343)
222. Lesser, G J; Grossman, S A; Eller, S; Rowinsky, E K. "The distribution of systemically administered [3H]-paclitaxel in rats: a quantitative autoradiographic study". *Cancer chemotherapy & pharmacology*. 1995; 37: 173 (#144348)
223. O'Reilly, S; Kennedy, M J; Rowinsky, E K; Donehower, R C. "Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy". *Breast cancer research & treatment*. 1995; 33: 1 (#144346)
224. Rowinsky, E K. "The suitability of selected new anticancer agents for infusional therapy and the effects of others on infusional therapy practices". *Journal of infusional chemotherapy*. 1995; 5: 173 (#144340)
225. Rowinsky, E K; Donehower, R C. "Paclitaxel (taxol)". *New England journal of medicine*. 1995; 332: 1004 (#144344)
226. Rowinsky, E K; Flood, W A; Sartorius, S E; Bowling, M K; Wagner, J; Ettinger, D S. "Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer". *Seminars in oncology*. 1995; 22: 48 (#144342)
227. Rowinsky, E K; Noe, D A; Grochow, L B; Sartorius, S E; Bowling, M K; Chen, T L; Lubejko, B G; Kaufmann, S H; Donehower, R C. "Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA

- intercalating agent, on single-dosing and multiple-dosing schedules". *Journal of clinical oncology*. 1995; 13: 1975 (#144341)
228. Slichenmyer, W J; Donehower, R C; Chen, T L; Bowling, M K; McGuire, W P; Rowinsky, E K. "Pretreatment H2 receptor antagonists that differ in P450 modulation activity: comparative effects on paclitaxel clearance rates and neutropenia". *Cancer chemotherapy & pharmacology*. 1995; 36: 227 (#144347)
229. Sollott, S J; Cheng, L; Pauly, R R; Jenkins, G M; Monticone, R E; Kuzuya, M; Froehlich, J P; Crow, M T; Lakatta, E G; Rowinsky, E K. "Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat". *Journal of clinical investigation*. 1995; 95: 1869 (#144345)
230. Borkowski, J M; Duerr, M; Donehower, R C; Rowinsky, E K; Chen, T L; Ettinger, D S; Grochow, L B. "Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data". *Cancer chemotherapy & pharmacology*. 1994; 33: 493 (#144356)
231. Chaudhry, V; Rowinsky, E K; Sartorius, S E; Donehower, R C; Cornblath, D R. "Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies". *Annals of neurology*. 1994; 35: 304 (#144353)
232. Finley, R S; Rowinsky, E K. "Patient care issues: the management of paclitaxel-related toxicities". *Annals of pharmacotherapy*. 1994; 28: S27 (#144351)
233. Rowinsky, E K. "Update on the antitumor activity of paclitaxel in clinical trials". *Annals of pharmacotherapy*. 1994; 28: S18 (#144352)
234. Rowinsky, E K; Adjei, A; Donehower, R C; Gore, S D; Jones, R J; Burke, P J; Cheng, Y C; Grochow, L B; Kaufmann, S H. "Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia". *Journal of clinical oncology*. 1994; 12: 2193 (#144349)
235. Rowinsky, E K; Grochow, L B; Ettinger, D S; Sartorius, S E; Lubejko, B G; Chen, T L; Rock, M K; Donehower, R C. "Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks". *Cancer research*. 1994; 54: 427 (#144354)
236. Rowinsky, E K; Noe, D A; Trump, D L; Winer, E P; Lucas, V S; Wargin, W A; Hohneker, J A; Lubejko, B; Sartorius, S E; Ettinger, D S. "Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors". *Journal of clinical oncology*. 1994; 12: 1754 (#144350)
237. Rowinsky, E K; Wright, M; Monsarrat, B; Donehower, R C. "Clinical pharmacology and metabolism of Taxol (paclitaxel): update 1993". *Annals of oncology*. 1994; 5 Suppl 6: S7 (#144355)
238. Slichenmyer, W J; Rowinsky, E K; Grochow, L B; Kaufmann, S H; Donehower, R C. "Camptothecin analogues: studies from the Johns Hopkins Oncology Center". *Cancer chemotherapy & pharmacology*. 1994; 34 Suppl: S53 (#144357)
239. Donehower, R C; Rowinsky, E K. "An overview of experience with TAXOL (paclitaxel) in the U.S.A". *Cancer treatment reviews*. 1993; 19 Suppl C: 63 (#144365)
240. Monsarrat, B; Alvinerie, P; Wright, M; Dubois, J; Gueritte-Voegelein, F; Guenard, D; Donehower, R C; Rowinsky, E K. "Hepatic metabolism and biliary excretion of Taxol in rats and humans". *Journal of the National Cancer Institute. Monographs*. 1993; 39 (#144367)
241. Peereboom, D M; Donehower, R C; Eisenhauer, E A; McGuire, W P; Onetto, N; Hubbard, J L; Piccart, M; Gianni, L; Rowinsky, E K. "Successful re-treatment with taxol after major hypersensitivity reactions". *Journal of clinical oncology*. 1993; 11: 885 (#144361)
242. Rowinsky, E K. "Clinical pharmacology of Taxol". *Journal of the National Cancer Institute. Monographs*. 1993; 25 (#144368)
243. Rowinsky, E K; Chaudhry, V; Cornblath, D R; Donehower, R C. "Neurotoxicity of Taxol". *Journal of the National Cancer Institute. Monographs*. 1993; 107 (#144369)
244. Rowinsky, E K; Chaudhry, V; Forastiere, A A; Sartorius, S E; Ettinger, D S; Grochow, L B; Lubejko, B G; Cornblath, D R; Donehower, R C. "Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting". *Journal of clinical oncology*. 1993; 11: 2010 (#144358)
245. Rowinsky, E K; Citardi, M J; Noe, D A; Donehower, R C. "Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine". *Journal of cancer research & clinical oncology*. 1993; 119: 727 (#144366)
246. Rowinsky, E K; Donehower, R C. "The clinical pharmacology of paclitaxel (Taxol)". *Seminars in oncology*. 1993; 20: 16 (#144359)
247. Rowinsky, E K; Eisenhauer, E A; Chaudhry, V; Arbuck, S G; Donehower, R C. "Clinical toxicities encountered with paclitaxel (Taxol)". *Seminars in oncology*. 1993; 20: 1 (#144360)
248. Rowinsky, E K; Noe, D A; Ettinger, D S; Christian, M C; Lubejko, B G; Fishman, E K; Sartorius, S E; Boyd, M R; Donehower, R C. "Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans". *Cancer research*. 1993; 53: 1794 (#144362)
249. Rowinsky, E K; Wright, M; Monsarrat, B; Lesser, G J; Donehower, R C. "Taxol: pharmacology, metabolism and clinical implications". *Cancer surveys*. 1993; 17: 283 (#144364)
250. Slichenmyer, W J; Rowinsky, E K; Donehower, R C; Kaufmann, S H. "The current status of camptothecin analogues as antitumor agents". *Journal of the National Cancer Institute*. 1993; 85: 271 (#144363)
251. Grochow, L B; Rowinsky, E K; Johnson, R; Ludeman, S; Kaufmann, S H; McCabe, F L; Smith, B R; Hurowitz, L; DeLisa, A; Donehower, R C. "Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer". *Drug metabolism & disposition*. 1992; 20: 706 (#144371)

252. Hendricks, C B; Rowinsky, E K; Grochow, L B; Donehower, R C; Kaufmann, S H. "Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue". *Cancer research*. 1992; 52: 2268 (#144373)
253. Rowinsky, E K; Conley, B A; Jones, R J; Spivak, J L; Auerbach, M; Donehower, R C. "Hexamethylene bisacetamide in myelodysplastic syndrome: effect of five-day exposure to maximal therapeutic concentrations". *Leukemia*. 1992; 6: 526 (#144372)
254. Rowinsky, E K; Grochow, L B; Hendricks, C B; Ettinger, D S; Forastiere, A A; Hurowitz, L A; McGuire, W P; Sartorius, S E; Lubejko, B G; Kaufmann, S H. "Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor". *Journal of clinical oncology*. 1992; 10: 647 (#144374)
255. Rowinsky, E K; Onetto, N; Canetta, R M; Arbuck, S G. "Taxol: the first of the taxanes, an important new class of antitumor agents". *Seminars in oncology*. 1992; 19: 646 (#144370)
256. Hendricks, C B; Grochow, L B; Rowinsky, E K; Forastiere, A A; McGuire, W P; Ettinger, D S; Sartorius, S; Lubejko, B; Donehower, R C. "Phase I and pharmacokinetic study of hepsulfam (NSC 329680)". *Cancer research*. 1991; 51: 5781 (#144377)
257. McGuire, W P; Rowinsky, E K. "Old drugs revisited, new drugs, and experimental approaches in ovarian cancer therapy". *Seminars in oncology*. 1991; 18: 255 (#144381)
258. Rowinsky, E K. "Current developments in antitumor antibiotics, epipodophyllotoxins, and vinca alkaloids". *Current opinion in oncology*. 1991; 3: 1060 (#144376)
259. Rowinsky, E K; Donehower, R C. "Taxol: twenty years later, the story unfolds". *Journal of the National Cancer Institute*. 1991; 83: 1778 (#144375)
260. Rowinsky, E K; Donehower, R C. "The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics". *Pharmacology & therapeutics*. 1991; 52: 35 (#144378)
261. Rowinsky, E K; Gilbert, M R; McGuire, W P; Noe, D A; Grochow, L B; Forastiere, A A; Ettinger, D S; Lubejko, B G; Clark, B; Sartorius, S E. "Sequences of taxol and cisplatin: a phase I and pharmacologic study". *Journal of clinical oncology*. 1991; 9: 1692 (#144380)
262. Rowinsky, E K; McGuire, W P; Guarnieri, T; Fisherman, J S; Christian, M C; Donehower, R C. "Cardiac disturbances during the administration of taxol". *Journal of clinical oncology*. 1991; 9: 1704 (#144379)
263. Hantel, A; Donehower, R C; Rowinsky, E K; Vance, E; Clarke, B V; McGuire, W P; Ettinger, D S; Noe, D A; Grochow, L B. "Phase I study and pharmacodynamics of piroxantrone (NSC 349174), a new anthrapyrazole". *Cancer research*. 1990; 50: 3284 (#144385)
264. Jones, R J; Sharkis, S J; Miller, C B; Rowinsky, E K; Burke, P J; May, W S. "Bryostatins 1, a unique biologic response modifier: anti-leukemic activity in vitro". *Blood*. 1990; 75: 1319 (#144386)
265. Noe, D A; Rowinsky, E K; Shen, H S; Clarke, B V; Grochow, L B; McGuire, W B; Hantel, A; Adams, D B; Abeloff, M D; Ettinger, D S. "Phase I and pharmacokinetic study of brequinar sodium (NSC 368390)". *Cancer research*. 1990; 50: 4595 (#144383)
266. Roberts, J R; Allison, D C; Donehower, R C; Rowinsky, E K. "Development of polyploidization in taxol-resistant human leukemia cells in vitro". *Cancer research*. 1990; 50: 710 (#144387)
267. Rowinsky, E K; Cazenave, L A; Donehower, R C. "Taxol: a novel investigational antimicrotubule agent". *Journal of the National Cancer Institute*. 1990; 82: 1247 (#144384)
268. Rowinsky, E K; Donehower, R C; Spivak, J L; Burke, P J; Griffin, C A; Jones, R J. "Effects of the differentiating agent hexamethylene bisacetamide on normal and myelodysplastic hematopoietic progenitors". *Journal of the National Cancer Institute*. 1990; 82: 1926 (#144382)
269. Grochow, L B; Noe, D A; Dole, G B; Rowinsky, E K; Ettinger, D S; Graham, M L; McGuire, W P; Donehower, R C. "Phase I trial of trimetrexate glucuronate on a five-day bolus schedule: clinical pharmacology and pharmacodynamics". *Journal of the National Cancer Institute*. 1989; 81: 124 (#144392)
270. McGuire, W P; Rowinsky, E K; Rosenshein, N B; Grumbine, F C; Ettinger, D S; Armstrong, D K; Donehower, R C. "Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms". *Annals of internal medicine*. 1989; 111: 273 (#144390)
271. Roberts, J R; Rowinsky, E K; Donehower, R C; Robertson, J; Allison, D C. "Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells". *Journal of histochemistry & cytochemistry*. 1989; 37: 1659 (#144389)
272. Rowinsky, E K; Burke, P J; Karp, J E; Tucker, R W; Ettinger, D S; Donehower, R C. "Phase I and pharmacodynamic study of taxol in refractory acute leukemias". *Cancer research*. 1989; 49: 4640 (#144391)
273. Rowinsky, E K; Grochow, L B; Hantel, A; Ettinger, D S; Vito, B L; Donehower, R C. "Assessment of N-methylformamide (NMF) administered orally on a three times weekly schedule: a phase I study". *Investigational new drugs*. 1989; 7: 317 (#144388)
274. Hantel, A; Rowinsky, E K; Donehower, R C. "Nifedipine and oncologic Raynaud phenomenon". *Annals of internal medicine*. 1988; 108: 767 (#144396)
275. Hantel, A; Rowinsky, E K; Noe, D A; McGuire, W P; Grochow, L B; Vito, B L; Ettinger, D S; Donehower, R C. "Clinical and pharmacologic reappraisal of dichloromethotrexate". *Journal of the National Cancer Institute*. 1988; 80: 1547 (#144393)
276. Rowinsky, E K; Donehower, R C; Jones, R J; Tucker, R W. "Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol". *Cancer research*. 1988; 48: 4093 (#144394)
277. Rowinsky, E K; Noe, D A; Orr, D W; Grochow, L B; Ettinger, D S; Donehower, R C. "Clinical pharmacology of oral and i.v. N-methylformamide: a pharmacologic basis for lack of clinical antineoplastic activity".

- Journal of the National Cancer Institute*. 1988; 80: 671 (#144395)
278. Donehower, R C; Rowinsky, E K; Grochow, L B; Longnecker, S M; Ettinger, D S. "Phase I trial of taxol in patients with advanced cancer". *Cancer treatment reports*. 1987; 71: 1171 (#144397)
279. Rowinsky, E K; Ettinger, D S; McGuire, W P; Noe, D A; Grochow, L B; Donehower, R C. "Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study". *Cancer research*. 1987; 47: 5788 (#144398)
280. Rowinsky, E K; Harwood, K V; Ettinger, D S. "Sudden dyspnea occurring 24 hours after mitomycin plus etoposide combination therapy". *Cancer treatment reports*. 1987; 71: 103 (#144400)
281. Rowinsky, E K; McGuire, W P; Anhalt, G J; Ettinger, D S; Donehower, R C. "Hexamethylene bisacetamide-induced cutaneous vasculitis". *Cancer treatment reports*. 1987; 71: 471 (#144399)
282. Rowinsky, E K; Ettinger, D S; Grochow, L B; Brundrett, R B; Cates, A E; Donehower, R C. "Phase I and pharmacologic study of hexamethylene bisacetamide in patients with advanced cancer". *Journal of clinical oncology*. 1986; 4: 1835 (#144401)
283. Rowinsky, E K; Jones, R J; Abeloff, M D. "Massive adrenal hemorrhage secondary to metastatic lung carcinoma". *Medical & pediatric oncology*. 1986; 14: 234 (#144402)
284. Rowinsky, E K; Abeloff, M D; Wharam, M D. "Spontaneous pneumothorax following thoracic irradiation". *Chest*. 1985; 88: 703 (#144403)

All data from NYU Health Sciences Library Faculty Bibliography

NYU Faculty may edit their publications and access other personalized services at <http://myinfo.med.nyu.edu>

or see: <http://library.med.nyu.edu/library/eresources/faculty/bib-faq.html>

[Ethics](#) • [Disclaimer](#) • [Privacy Policy](#) • [Contact Webmaster](#)

© 2011 Division of Hematology & Medical Oncology | Department of Medicine | 550 First Avenue, New York, NY 10016

Call us for more information:
212-263-9015
**NYU Langone**
MEDICAL CENTER